Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumour in humans and has a very poor prognosis. The existing treatments have had limited …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

Evidence implicating Eph receptor tyrosine kinases and their ephrin ligands (that together
make up the 'Eph system') in cancer development and progression has been accumulating …

Glioblastoma multiforme (GBM) is a highly lethal and aggressive tumor of the brain that
carries a poor prognosis. Temozolomide (TMZ) has been widely used as a first-line …

Eph receptor tyrosine kinases play critical functions during development, in the formation of
tissue and organ borders, and the vascular and neural systems. Uniquely among tyrosine …

Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma
(GB) remains a challenge. The current survival rate of GB averages one year, even with an …

Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has
limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a …

The Eph subfamily of receptor tyrosine kinases mediate cell-cell communication controlling
cell and tissue patterning during development. While generally less active in adult tissues …

The erythropoietin-producing human hepatocellular (Eph) receptors are transmembrane
glycoprotein members of the tyrosine kinase receptors family. The Ephs may bind to various …

Antibody-drug conjugates offer the possibility of directing powerful cytotoxic agents to a
malignant tumor while sparing normal tissue. The challenge is to select an antibody target …